Lab Automation Market is expected to reach US$ 8.71 Billion by 2031

Personalized Medicine & Precision Diagnostics Fuel Lab Automation Market   

According to our latest study, “Lab Automation Market Size and Forecast (2021–2031), Global and Regional Share, Trend, and Growth Opportunity Analysis – by Type, Application, End User, and Geography," the market was valued at US$ 5.76 billion in 2024 and is expected to reach US$ 8.71 billion by 2031; it is estimated to record a CAGR of 6.3% during 2025–2031. The report includes growth prospects owing to current lab automation market trends and their foreseeable impact during the forecast period.

The lab automation market is significantly influenced by the rapid growth of personalized medicine and precision diagnostics, as healthcare and life sciences change from generalized treatment methods to patient-specific interventions. Personalized medicine is dependent on genomic, proteomic, and metabolomic data to produce tailored therapies to each individual’s unique biological profile. This necessitates handling and analysis of a very large amount of biological samples with a high degree of accuracy, reproducibility, and speed - all of which are features that automated laboratory systems are capable of delivering.

Lab Automation Market Analysis — by Geography

Source: The Insight Partners Analysis

Through high-throughput sample preparation, automation technologies allow for operations such as nucleic acid extraction and next-generation sequencing (NGS) to be performed. At the same time, they reduce the risk of human error and variability. The demand for personalized therapeutics, in particular, in the field of oncology, rare diseases, and pharmacogenomics, has led to the development of labs that are capable of performing large-scale operations while at the same time maintaining data quality and compliance.

Precision diagnostics is a major factor in early disease detection, treatment, and monitoring; consequently, lab automation is highly demanded. The integration of molecular and genetic testing into the routine healthcare workflows necessitates the consistent and rapid processing of patient samples, which manual processing at such large volumes is not able to provide. Automated solutions not only accelerate diagnostic turnaround times but also provide better traceability and standardization, which are key in the regulatory sphere and clinical accuracy.

The wearables and digital biomarkers, as they keep coming up with new ways of making the health monitoring more technological and accurate, are producing much complex data. Laboratories now have no other option but to rely on integrated, data-driven automation systems if they want to be capable of analyzing and making decisions on the spot. Personalized healthcare, digital health, and laboratory automation are at a crossroads of a market boom. The businesses that offer automation solutions that are scalable, interoperable as well and AI-enabled are strategically located to respond to the needs of their rapidly expanding market segment; thus, the future of precision medicine and laboratory innovation largely depends on these firms.

Thermo Fisher Scientific Inc.; Siemens AG; Danaher Corp; Honeywell International Inc; Agilent Technologies Inc; Revvity Inc; Analytik Jena GmbH+Co. KG; Abbott Laboratories; Eppendorf SE; and bioMerieux SA are among the key players profiled in the lab automation market report. Other major players were also studied and analyzed during the market study to get a holistic view of the market and its ecosystem. 

The report includes the lab automation market forecast by type, equipment, application, and end user. By application, the lab automation market is segmented into clinical diagnostics, drug discovery, proteomics solutions, genomics solutions, and others. Clinical diagnostics is the leading example of a major application area in the lab automation market. Automation in this field is targeted to improve the diagnostic testing’s speed, accuracy, and repeatability, especially in environments with a high throughput, such as hospital labs, pathology centers, and national diagnostic facilities. Automated systems take the initiative for both the normal and the specialized tasks that are performed along the workflows. These tasks include sample sorting, barcode scanning, centrifugation, reagent dispensing, analyte detection, and result reporting. Besides the fact that the systems execute these tasks, they also achieve the goal of smoother workflows by alleviating the chances of human errors and shortening the turnaround time, which is very important for making clinical decisions within the required time. This segment held the largest lab automation market share in 2024.

The scope of the lab automation market report focuses on North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), the Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). North America dominated the market in 2024, followed by Europe and the Asia Pacific.

The lab automation market in the Asia Pacific is segmented into Australia, China, Japan, India, South Korea, and the Rest of the Asia Pacific. In terms of revenue, China held the largest lab automation market share in the Asia Pacific. China is the fastest-growing lab automation market in the region, driven by rapid industrialization, healthcare modernization, and massive investments in biotechnology and precision medicine. Strategic national projects of China - for instance, ‘Healthy China 2030’ and its goal of being the frontrunner in genomics and artificial intelligence - are the reasons for the solid demand for the most advanced high-throughput laboratory automation systems in the world. The automated platforms are being used in hospitals, public-health institutions, and life-sciences companies to handle the increasing workloads, which are clinical diagnostics, genomic sequencing, and pharmaceutical R&D. Domestic innovator MGI Tech is deploying automation solutions for sample preparation and genetic sequencing in major institutions and national health programs, escalating the technology pool across the nation. At the same time, multinational companies such as Thermo Fisher Scientific, Beckman Coulter, and Roche Diagnostics are utilizing local collaborations and manufacturing to broaden their horizons in the region. Considering the population, it is predicted that the need for lab automation will grow at a very high pace, especially in Tier 1 and Tier 2 cities in China.

With all the increased demands for efficiency, higher throughput, and better sustainability, labs not only in Europe but all over the world are struggling. It becomes clear that they need sophisticated automation solutions that are more delicate and multifunctional. Corresponding to this scenario, QIAGEN - a global leader in life sciences and molecular diagnostics - is undergoing a strategic amplification of its portfolio of technologies for automated sample prep. The company plans to progressively unveil three new automated systems over 2025 and 2026, as a result of which it will continue to innovate and maintain its strong position in the rapidly developing sector of laboratory automation, says the company. On the 15th of April, 2025, QIAGEN delivered an important point on its course with a detailed account about the forthcoming instruments to facilitate operational performance and environmental sustainability in laboratories around the globe. One of the expected innovations is QIAsymphony Connect, which represents a significant update of the QIAsymphony platform, the main framework of the majority of the currently available devices, and thus has been installed in more than 3,300 places worldwide. The deployment of QIAsymphony Connect will be a gradual process, starting with a small group of users in 2025, where the new functions will be customized to cater to the sophisticated laboratory needs of the 21st century.

Contact Us

Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com